India’s Sun Pharma Begins Open Offer For Taro at $7.75
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Sun Pharma said its Alkaloida Chemical unit started a tender offer for all shares of Israel's Taro Pharmaceutical as part of a disputed $460 million merger agreement reached a year ago, but unilaterally cancelled by Taro in late May
You may also be interested in...
Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair
MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2
Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair
MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2
Indian Sectors Spiral Downward While Pharma Remains Best Performer
MUMBAI - Pharma scrips listed on Indian bourses have emerged among the best performers in the downturn that has hit the country's stock markets. The Health Care Index, which is representative of pharma stocks on the Bombay Stock Exchange, has gained 10.2 percent in value over the last year, while most other sectors saw erosion in value from peak levels in June 2007